Myths vs facts: CYP1A2 and Langlebigkeit

CYP1A2 is an enzyme involved in metabolizing caffeine and some drugs. Common variants (e.g., rs762551) are labeled 'fast' or 'slow' metabolizers. Claims that 'slow' metabolizers have higher cardiovascular risk and thus shorter lifespan are widespread but poorly supported. While some association studies link CYP1A2 variants to caffeine intake and blood pressure, direct evidence for an effect on longevity is lacking. Longevity is a complex trait influenced by many genes, lifestyle, and environment; a single CYP1A2 variant has at most a minor, context-dependent role. Marketing that positions CYP1A2 as a 'longevity gene' overstates the science. Consumer DNA tests can indicate predisposition but are not diagnostic. Individuals can adjust caffeine consumption based on personal tolerance without genetic testing. The evidence level is mechanistic/unclear, not human-strong.